We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Disrupting Glutamine Metabolism Slows Liver Cancer Growth

By LabMedica International staff writers
Posted on 23 Jun 2016
Print article
Image: A fluorescent microscope image of liver cells and the chemical structure of glutamine (Photo courtesy of Dr. Kristina Schoonjans, Ecole Polytechnique Fédérale de Lausanne).
Image: A fluorescent microscope image of liver cells and the chemical structure of glutamine (Photo courtesy of Dr. Kristina Schoonjans, Ecole Polytechnique Fédérale de Lausanne).
Cancer researchers used a line of genetically engineered mice to demonstrate the dependency of liver cancer cells on the amino acid glutamine as their primary energy source.

Investigators at the Ecole Polytechnique Fédérale de Lausanne (Switzerland) worked with a line of "knock-out" mice that had been genetically engineered to lack the gene for production of the enzyme LRH-1 (liver receptor homolog 1). LRH-1 is a member of the nuclear receptor family of intracellular transcription factors and plays a critical role in the regulation of development, cholesterol transport, bile acid homeostasis, and steroidogenesis.

The investigators reported in the June 1, 2016, issue of the journal Genes & Development that gain and loss of function of LRH-1 in the liver modulated the expression and activity of mitochondrial glutaminase 2 (GLS2), the first and rate-limiting step of the glutamine pathway.

Closing down this pathway by eliminating LRH-1 prevented the utilization of glutamine as a fuel and put the cancerous cells into tremendous metabolic distress. Acute and chronic deletion of LRH-1 in the liver prevented the deamination of glutamine and reduced glutamine-dependent anaplerosis (the process of replenishment of depleted metabolic cycle or pathway intermediates).

The reduction in the lysis of glutamine limited the availability of alpha-ketoglutarate, which in turn inhibited mTORC1 (mammalian target of rapamycin (mTOR) complex 1) signaling to eventually block cell growth and proliferation.

"Inhibiting LRH-1 can thus be an effective way to starve only liver cancer cells, while leaving normal cells intact," said contributing author Dr. Kristina Schoonjans, head of the laboratory of metabolic signaling at the Ecole Polytechnique Fédérale de Lausanne.

Related Links:
Ecole Polytechnique Fédérale de Lausanne

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.